登录

Humana是第一家为青少年提供TMS治疗覆盖的商业付款人

Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents

BioSpace 等信源发布 2024-05-15 19:53

可切换为仅中文


Policy change comes quickly after FDA clearance for NeuroStar TMS use in ages 15 and older

FDA批准15岁及以上的NeuroStar TMS使用后,政策迅速改变

MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders announced today that Humana has become the first commercial payer to update its policy in response to the Company’s recent clearance from the U.S.

宾夕法尼亚州马尔文(MALVERN),2024年5月15日(Global NEWSWIRE)--Neuronetics,Inc.(纳斯达克:STIM),一家专注于设计、开发和营销改善神经健康障碍患者生活质量的产品的医疗技术公司,今天宣布Humana已成为首个更新其政策的商业付款人,以应对该公司最近从美国获得的许可。

Food and Drug Administration (FDA) for NeuroStar TMS (transcranial magnetic stimulation) as a first-line add-on for adolescents aged 15-21 with MDD (major depressive disorder)..

美国食品和药物管理局(FDA)将NeuroStar TMS(经颅磁刺激)作为15-21岁MDD(重度抑郁症)青少年的一线附加产品。。

Humana policies cover approximately 600,000 commercial lives in the United States. Prior to the recent policy update, Humana’s TMS coverage extended to individuals 18 years and older. The revision now addresses requests for TMS treatment for adolescents 15-17 years of age as requiring review by a medical director.

Humana的政策涵盖了美国大约60万个商业生活。在最近的政策更新之前,Humana的TMS覆盖范围扩展到18岁及以上的个人。修订版现在针对15-17岁青少年的TMS治疗要求,需要由医疗主管进行审查。

The effective date for this change was April 25, 2024, only one month after the NeuroStar FDA clearance was announced on March 25, 2024..

这一变更的生效日期是2024年4月25日,也就是2024年3月25日宣布NeuroStar FDA批准后的一个月。。

“The FDA clearance for NeuroStar TMS is the most significant treatment advancement in years for the often-underserved adolescent patient population. Humana’s quick action to acknowledge NeuroStar’s availability for young people 15 and older underscores this urgent mental health need,” stated Keith J.

Keith J。

Sullivan, President & CEO of Neuronetics, Inc. “We’re also gratified to see that our health policy strategy is contributing to positive policy changes for TMS coverage. Collectively, our efforts will benefit not only the young people affected by depression, but also their parents and families who are looking for a way to help them.”.

Neuronetics,Inc.总裁兼首席执行官苏利文(Sullivan)表示:“我们也很高兴看到,我们的健康政策战略正在为TMS覆盖率的积极政策变化做出贡献。总的来说,我们的努力不仅会使受抑郁症影响的年轻人受益,还会使他们的父母和家人受益,他们正在寻找帮助他们的方法。”。

Neuronetics is uniquely positioned to effect change, as the first and only TMS company with this clearance, and as the only TMS company in the industry with a dedicated health policy team that partners with both providers and payors to advocate for health policy updates.

作为第一家也是唯一一家获得这种许可的TMS公司,Neuronetics在实现变革方面具有独特的地位,也是业界唯一一家拥有专门健康政策团队的TMS公司,该团队与提供者和付款人合作,倡导健康政策更新。

For more information about NeuroStar TMS Therapy, please visit www.neurostar.com.

有关NeuroStar TMS治疗的更多信息,请访问www.NeuroStar.com。

About Adolescent Depression

关于青少年抑郁症

Adolescent depression is a complex and challenging mental health condition that affects young individuals during the crucial period of adolescence. An estimated 4.3 million U.S. adolescents aged 15-21 are affected by MDDi. Depression amongst adolescents can disrupt crucial aspects of development, such as academic performance, relationships with peers and family members, and overall emotional well-being..

青少年抑郁症是一种复杂且具有挑战性的心理健康状况,在青春期的关键时期会影响年轻人。据估计,美国有430万15-21岁的青少年受到MDDi的影响。青少年的抑郁症会破坏发展的关键方面,如学业成绩、与同龄人和家庭成员的关系以及整体情绪健康。。

NeuroStar Advanced Therapy is indicated as an adjunct for the treatment of MDD in adolescent patients aged 15-21.

NeuroStar Advanced Therapy被认为是15-21岁青少年MDD治疗的辅助手段。

AboutNeuronetics

关于神经学

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped.

Neuronetics,Inc.认为心理健康与身体健康同等重要。作为神经科学领域的全球领导者,Neuronetics正在通过其NeuroStar Advanced Therapy for Mental Health重新定义患者和医生的期望。NeuroStar是一种非药物、无创的治疗方法,可以在传统药物无效的情况下改善神经健康状况患者的生活质量。

NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode.

NeuroStar适用于治疗抑郁症发作和减少焦虑症状,这些患者可能在患有MDD的成年患者中表现出共病焦虑症状,并且在当前发作中未能从先前的抗抑郁药物治疗中获得令人满意的改善。

It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 6.4 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results.

它也被FDA批准为强迫症成人和15-21岁MDD青少年患者的辅助药物。NeuroStar Advanced Therapy是成人MDD的领先TMS治疗方法,提供了640多万次治疗。神经元学致力于通过提供产生非凡结果的特殊治疗来改变生活。

For safety and prescribing information, visit www.neurostar.com..

有关安全和处方信息,请访问www.neurostar.com。。

Media Contact:

媒体联系人:

EvolveMKD

EvolveMKD

646.517.4220

646.517.4220

NeuroStar@evolvemkd.com

NeuroStar@evolvemkd.com

i World Health Organization, Depression Fact Sheet. Accessed April 29, 2024. https://www.who.int/news-room/fact-sheets/detail/depression.

i世界卫生组织,抑郁症概况。2024年4月29日访问。https://www.who.int/news-room/fact-sheets/detail/depression.